Nonmotor Aspects of Parkinson's Disease

Blue Books of Neurology

Volumn 34, Issue C, 2010, Pages 229-251

  Tolosa, Eduardo ^a   Santamaria, Joan ^a   Gaig, Carles ^a   Compta, Yaroslau ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885982317     PISSN: 1877184X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-1-4160-6641-5.00014-3     Document Type: Chapter

References (209)

1. Doty, R.L., Stern, M.B., Pfeiffer, C., et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992), 138–142.
2. Katzenschlager, R., Lees, A.J., Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 17 (2004), 417–423.
3. Müller, A., Müngersdorf, M., Reichmann, H., et al. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 9 (2002), 521–524.
4. Henderson, J.M., Lu, Y., Wang, S., et al. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J Neurol Neurosurg Psychiatry 74 (2003), 956–958.
5. Ponsen, M.M., Stoffers, D., Booij, J., et al. Idiopathic hyposmia as a premotoral sign of Parkinson's disease. Ann Neurol 56 (2004), 173–181.
6. Doty, R.L., Golbe, L.I., McKeown, D.A., et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 43 (1993), 962–965.
7. Wenning, G.K., Shephard, B., Magalhaes, M., et al. Olfactory function in multiple system atrophy. Neurodegeneration 2 (1993), 169–171.
8. Wenning, G.K., Shephard, B.C., Hawkes, C.H., et al. Olfactory function in progressive supranuclear palsy and corticobasal degeneration. J Neurol Neurosurg Psychiatry 57 (1995), 251–252.
9. Wenning, G.K., Shephard, B., Hawkes, C., et al. Olfactory function in atypical Parkinsonian syndromes. Acta Neurol Scand 91 (1995), 247–250.
10. Abele, M., Riet, A., Hummel, T., et al. Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. J Neurol 250 (2003), 1453–1455.
11. Katzenschlager, R., Zijlmans, J., Lees, A.J., Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. Eur J Neurol 9:Suppl 2 (2002), 27–28.
12. Lee, P.H., Yeo, S.H., Yong, S.W., Kim, Y.J., Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 78 (2007), 1250–1252.
13. Louis, E.D., Bromley, S.M., Jurewicz, E.C., Watner, D., Olfactory dysfunction in essential tremor. Neurology 59 (2002), 1631–1633.
14. Khan, N.L., Katzenschlager, R., Watt, H., et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 62 (2004), 1224–1226.
15. McShane, R.H., Nagy, Z., Esiri, M.M., et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. J Neurol Neurosurg Psychiatry 70 (2001), 739–743.
16. Parkinson, J., An Essay on the Shaking Palsy. 1817, Sherwood, Neely, & Jones, London.
17. Gross, M., Bannister, R., Godwin-Ansten, R., Orthostatic hypotension in Parkinson's disease. Lancet 1 (1972), 174–176.
18. Goetz, C.G., Lutge, W., Tanner, C.M., Autonomic dysfunction in Parkinson's disease. Neurology 36 (1986), 73–75.
19. Goldstein, D.S., Holmes, C.S., Dendi, R., et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58 (2002), 1247–1255.
20. Magerkurth, C., Schnitzer, R., Braune, S., Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 15 (2005), 76–82.
21. Woodford, H., Walker, R., Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 20 (2005), 1104–1108.
22. Chaudhuri, K.R., Martinez-Martin, P., Schapira, A.H.V., et al. An international multicentre pilot study of the first comprehensive self-completed non motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21 (2006), 916–923.
23. Verbaan, D., Marinus, J., Visser, M., et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 69 (2007), 333–341.
24. Allcock, L.M., Kenny, R.A., Mosimann, U.P., et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline?. Int J Geriatr Psychiatry 21 (2006), 778–783.
25. Papapetropoulos, S., Paschalis, C., Athanassiadou, A., et al. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 70 (2001), 662–665.
26. Singleton, A., Gwinn-Hardy, K., Sharabi, Y., et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127 (2004), 768–772.
27. Albanese, A., Valente, E.M., Romito, L.M., et al. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64 (2005), 1958–1960.
28. Goldstein, D.S., Imrich, R., Peckham, E., et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 69 (2007), 1580–1584.
29. Khan, N.L., Graham, E., Critchley, P., et al. Parkin disease: a phenotypic study of a large case series. Brain 126 (2003), 1279–1292.
30. Bonuccelli, U., Lucetti, C., Del Dotto, P., et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 60 (2003), 1400–1404.
31. Kaufmann, H., Nahm, K., Purohit, D., Wolfe, D., Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63 (2004), 1093–1095.
32. O'Sullivan, S.S., Holton, J.L., Massey, L.A., et al. Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy. J Neurol Neurosurg Psychiatry 79 (2008), 232–234.
33. Kaye, J., Gage, H., Kimber, A., et al. Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 21 (2006), 1270–1273.
34. Edwards, L.L., Pfeiffer, R.F., Quigley, E.M.M., et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6 (1991), 151–156.
35. Pfeiffer, R.F., Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2 (2003), 107–116.
36. Ashraf, W., Wszolek, Z.K., Pfeiffer, R.F., et al. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 10 (1995), 650–657.
37. Sakakibara, R., Odaka, T., Uchiyama, T., et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003), 268–272.
38. Bassotti, G., Maggio, D., Battaglia, E., et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000), 768–770.
39. Mathers, S.E., Kempster, P.A., Swash, M., Lees, A.J., Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon. J Neurol Neurosurg Psychiatry 51 (1988), 1503–1507.
40. Ashraf, W., Pfeiffer, R.F., Quigley, E.M., Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation. Mov Disord 9 (1994), 655–663.
41. Hermanowicz, N., Fatal gastroparesis in a patient with Parkinson's disease. Mov Disord 23 (2008), 152–153.
42. Sonnenberg, A., Tsou, V.T., Müller, A.D., The “institutional colon”: a frequent colonic dysmotility in psychiatric and neurologic disease. Am J Gastroenterol 89 (1994), 62–66.
43. Braak, H., Del Tredici, K., Rub, U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003), 197–211.
44. Benarroch, E.E., Schmeichel, A.M., Parisi, J.E., Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 54 (2000), 963–968.
45. Qualman, S.J., Haupt, H.M., Yang, P., Hamilton, S.R., Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson's disease. Gastroenterology 87 (1984), 848–856.
46. Jackson, M., Lennox, G., Balsitis, M., Lowe, J., Lewy body dysphagia. J Neurol Neurosurg Psychiatry 58 (1995), 756–758.
47. Singaram, C., Ashraf, W., Gaumnitz, E.A., et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346 (1995), 861–864.
48. Kupsky, W.J., Grimes, M.M., Sweeting, J., et al. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37 (1987), 1253–1255.
49. Braak, H., de Vos, R.A., Bohl, J., Del Tredici, K., Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396 (2006), 67–72.
50. Araki, I., Kuno, S., Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68 (2000), 429–433.
51. Campos-Sousa, R.N., Quagliato, E., da Silva, B.B., et al. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 61 (2003), 359–363.
52. Sakakibara, R., Shinotoh, H., Uchiyama, T., et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 92 (2001), 76–85.
53. Araki, I., Kitahara, M., Oida, T., Kuno, S., Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 164 (2000), 1640–1643.
54. Uchiyama, T., Sakakibara, R., Hattori, T., Yamanishi, T., Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 18 (2003), 573–578.
55. Fowler, C.J., Neurological disorders of micturition and their treatment. Brain 122 (1999), 1213–1231.
56. Wenning, G.K., Scherfler, C., Granata, R., et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 67 (1999), 620–623.
57. Pavlakis, A.J., Siroky, M.B., Goldstein, I., Krane, R.J., Neurourologic findings in Parkinson's disease. J Urol 129 (1983), 80–83.
58. Ransmayr, G.N., Holliger, S., Schletterer, K., et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 70 (2008), 299–303.
59. Bronner, G., Royter, V., Korczyn, A.D., Giladi, N., Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 30 (2004), 95–105.
60. Welsh, M., Hung, L., Waters, C.H., Sexuality in women with Parkinson's disease. Mov Disord 12 (1997), 923–927.
61. Wermuth, L., Stenager, E., Sexual problems in young patients with Parkinson's disease. Acta Neurol Scand 91 (1995), 453–455.
62. Jimenez-Jimenez, F.J., Tallon-Barranco, A., Cabrera-Valdivia, F., et al. Fluctuating penile erection related with levodopa therapy. Neurology, 52, 1999, 210.
63. Kanovsky, P., Bares, M., Pohanka, M., Rektor, I., Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 249 (2002), 112–114.
64. Wakabayashi, K., Takahashi, H., The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 94 (1997), 287–289.
65. Schatz, I.J., Bannister, R., Freeman, R.L., et al. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology, 46, 1996, 1470.
66. O'Mara, G., Lyons, D., Postprandial hypotension. Clin Geriatr Med 18 (2002), 307–321.
67. Bleasdale-Barr, K.M., Mathias, C.J., Neck and other muscle pains in autonomic failure: their association with orthostatic hypotension. J R Soc Med 91 (1998), 355–359.
68. Oka, H., Yoshioka, M., Onouchi, K., et al. Characteristics of orthostatic hypotension in Parkinson's disease. Brain 130 (2007), 2425–2432.
69. Goldstein, D.S., Holmes, C., Sharabi, Y., et al. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 60 (2003), 1327–1332.
70. Holmberg, B., Kallio, M., Johnels, B., Elam, M., Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of parkinsonian syndromes. Mov Disord 16 (2001), 217–225.
71. Ejaz, A.A., Sekhon, I.S., Munjal, S., Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur J Intern Med 17 (2006), 417–420.
72. Hakusui, S., Yasuda, T., Yanagi, T., et al. A radiological analysis of heart sympathetic functions with meta-(123I) iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49 (1994), 81–84.
73. Kashihara, K., Ohno, M., Kawada, S., Okumura, Y., Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 47 (2006), 1099–1101.
74. Orimo, S., Oka, T., Miura, H., et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73 (2002), 776–777.
75. Li, S.T., Dendi, R., Holmes, C., Goldstein, D.S., Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol 52 (2002), 220–223.
76. Hamada, K., Hirayama, M., Watanabe, H., et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003), 423–426.
77. Spiegel, J., Hellwig, D., Farmakis, G., et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 22 (2007), 1004–1008.
78. Matsui, H., Nishinaka, K., Oda, M., et al. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?. Parkinsonism Relat Disord 12 (2006), 284–288.
79. Takatsu, H., Nishida, H., Matsuo, H., et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 41 (2000), 71–77.
80. Taki, J., Nakajima, K., Hwang, E.H., et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27 (2000), 566–573.
81. de Milliano, P.A., van Eck-Smit, B.L., de Groot, A.C., Lie, K.I., Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease. Circulation 102 (2001), 2553–2554.
82. Schnell, O., Kirsch, C.M., Stemplinger, J., et al. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 38 (1995), 1345–1352.
83. Kujawa, K., Leurgans, S., Raman, R., et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 57 (2000), 1461–1463.
84. Goetz, C.G., Koller, W.C., Poewe, W., et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 17 (2002), S1–S166.
85. Horstink, M., Tolosa, E., Bonuccelli, U., et al. European Federation of Neurological Societies; Movement Disorder Society–European Section. Review of the therapeutic management of Parkinson's disease, part II: late (complicated) Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society–European Section (MDS-ES). Eur J Neurol 13 (2006), 1186–1202.
86. Eichhorn, T.E., Oertel, W.H., Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 16 (2001), 1176–1177.
87. Zangaglia, R., Martignoni, E., Glorioso, M., et al. Macrogol for the treatment of constipation in Parkinson's disease: a randomized placebo-controlled study. Mov Disord 22 (2007), 1239–1244.
88. Sullivan, K.L., Staffetti, J.F., Hauser, R.A., et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 21 (2006), 115–116.
89. Liu, Z., Sakakibara, R., Odaka, T., et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20 (2005), 680–686.
90. Sakakibara, R., Odaka, T., Lui, Z., et al. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord 20 (2005), 261–262.
91. Day, J.P., Pruitt, R.E., Diabetic gastroparesis in a patient with Parkinson's disease: effective treatment with domperidone. Am J Gastroenterol 84 (1989), 837–838.
92. Soykan, I., Sarosiek, I., Shifflett, J., et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 12 (1997), 952–957.
93. Jimenez-Jimenez, F.J., Garcia-Ruiz, P.J., Molina, J.A., Drug-induced movement disorders. Drug Saf 16 (1997), 180–204.
94. Cadeddu, F., Bentivoglio, A.R., Brandara, F., et al. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther 22 (2005), 997–1003.
95. Albanese, A., Brisinda, G., Bentivoglio, A.R., Maria, G., Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 98 (2003), 1439–1440.
96. Suchowersky, O., Furtado, S., Rohs, G., Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 10 (1995), 337–340.
97. Hussain, I.F., Brady, C.M., Swinn, M.J., et al. Treatment of erectile dysfunction with sildenafil citrate in parkinsonism due to Parkinson's disease and multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71 (2001), 371–374.
98. Zesiewicz, T.A., Helal, M., Hauser, R.A., Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 15 (2000), 305–308.
99. Raffaele, R., Vecchio, I., Giammusso, B., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Uroly 41 (2002), 382–386.
100. O'Sullivan, J.D., Hughes, A.J., Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13 (1998), 536–539.
101. O'Sullivan, J.D., Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry, 72, 2002, 681.
102. Pohanka, M., Kanovsky, P., Bares, M., et al. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol 11 (2004), 483–488.
103. Pohanka, M., Kanovsky, P., Bares, M., et al. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord 11 (2005), 509–512.
104. Hasegawa, Y., Hakusui, S., Hirayama, M., et al. Clinical effects of elastic bandage on neurogenic orthostatic hypotension. J Gravit Physiol 7 (2000), 159–160.
105. Smit, A.A., Wieling, W., Opfer-Gehrking, T.L., et al. Patients’ choice of portable folding chairs to reduce symptoms of orthostatic hypotension. Clin Auton Res 9 (1999), 341–344.
106. Lang, A.E., Acute orthostatic hypotension when starting dopamine agonist therapy in Parkinson disease: the role of domperidone therapy. Arch Neurol, 58, 2001, 835.
107. Jankovic, J., Gilden, J.L., Hiner, B.C., et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 95 (1993), 38–48.
108. Low, P.A., Gilden, F.L., Freeman, R., et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized double-blind multicenter study. Midodrine study group. JAMA 277 (1997), 1046–1051.
109. Hakamaki, T., Rajala, T., Lehtonen, A., Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther 36 (1998), 367–369.
110. Schoffer, K.L., Henderson, R.D., O'Maley, K., O'Sullivan, J.D., Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 22 (2007), 1543–1549.
111. Singer, W., Sandroni, P., Tonette, L., et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 63 (2006), 513–518.
112. Jansen, R.W., Lipsitz, L.A., Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 122 (1995), 286–295.
113. Senard, J.M., Brefel-Courbon, C., Rascol, O., Montastruc, J.L., Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18 (2001), 495–505.
114. Holmberg, B., Corneliusson, O., Elam, M., Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction. Mov Disord 20 (2005), 976–981.
115. Ludwig, J., Remien, P., Guballa, C., et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry 78 (2007), 742–745.
116. Lees, A.J., Blackburn, N.A., Campbell, V.L., The nighttime problems of Parkinson's disease. Clin Neuropharmacol 11 (1988), 512–519.
117. Iranzo, A., Molinuevo, J.L., Santamaria, J., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5 (2006), 572–577.
118. Basta, M., Schiza, S., Mauridis, M., et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Resp Med 97 (2003), 1151–1157.
119. Schenck, C., Mahowald, M.W., REM sleep behavior disorder: clinical, developmental and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 55 (2002), 281–288.
120. Gagnon, J.F., Bedard, M.A., Fantini, M.D., et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 59 (2002), 585–589.
121. Arnulf, I., Bonnet, M.A., Damier, P., et al. Hallucinations, REM sleep, and Parkinson's disease. Neurology 55 (2000), 281–288.
122. Scharf, B., Moskowitz, Ch., Lupton, M.D., Klawans, H.L., Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43 (1978), 143–151.
123. Nausieda, P.A., Weiner, W.J., Kaplan, L.R., et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5 (1982), 183–194.
124. Vendette, M., Gagnon, J.F., Décary, A., et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 69 (2007), 1843–1849.
125. Kumru, H., Santamaria, J., Tolosa, E., Iranzo, A., Relation between subtype of Parkinson's disease and REM sleep behavior disorder. Sleep Med 8 (2007), 779–783.
126. Frucht, S., Rogers, M.D., Greene, P.E., et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 58 (1999), 1908–1910.
127. Hobson, D.E., Lang, A.E., Martin, W.R., et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian movement disorder group. JAMA 287 (2002), 455–463.
128. Rascol, O., Ferreira, J., Montastruc, J.L., Somnolence diurne anormal, “attaques de sommeil” et médicaments antiparkinsoniens. Rev Neurol (Paris) 157 (2001), 1313–1315.
129. Tandberg, E., Larsen, J.P., Karlsen, K.A., A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 13 (1998), 895–899.
130. O'Suilleabhain, P.E., Dewey, R.B., Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 59 (2002), 986–989.
131. Tan, E.K., Lum, S.Y., Fook-Chong, S.M.C., et al. Evaluation of somnolence in Parkinson's disease: comparison with age and sex-matched controls. Neurology 58 (2002), 465–468.
132. Brodsky, M.A., Goldbold, J., Roth, T., Olanow, W.C., Sleepiness in Parkinson's disease: a controlled study. Mov Disord 18 (2003), 668–672.
133. Razmy, A., Lang, A.E., Shapiro, C.M., Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (Ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61 (2004), 97–102.
134. Stevens, S., Comella, C.L., Stepanski, E.J., Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 27 (2004), 967–972.
135. Factor, S.A., McAlarney, T., Sanchez-Ramos, J.R., Weiner, W.J., Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 5 (1990), 280–285.
136. Oerlemans, W.H., de Weerd, A.W., The prevalence of sleep disorders in patients with Parkinson's disease: a self-reported, community-based survey. Sleep Med 3 (2002), 147–149.
137. Verbaan, D., van Rooden, S.M., Visser, M., et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 23 (2008), 35–41.
138. Fabrinni, G., Barbanti, P., Aurilia, C., et al. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 17 (2002), 1026–1030.
139. Rye, D.B., Bliwise, D.L., Dihenia, B., Gurecki, P., Daytime sleepiness in Parkinson's disease. J Sleep Res 9 (2000), 63–69.
140. Young, A., Horne, M., Churchward, T., et al. Comparison of sleep disturbance in mild versus severe Parkinson's disease. Sleep 25 (2002), 568–572.
141. Roth, T., Rye, D.B., Borcher, L.D., et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 4 (2003), 275–280.
142. Gjerstad, M.D., Aarsland, D., Larsen, J.P., Development of daytime somnolence over time in Parkinson's disease. Neurology 58 (2002), 1544–1546.
143. Paus, S., Seeger, G., Brecht, H.M., et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov Disord 19 (2004), 705–707.
144. Rissling, I., Geller, F., Bandmann, O., et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting “sleep attacks.”. Mov Disord 19 (2004), 1279–1284.
145. Arnulf, I., Konofal, E., Merino-Andreu, M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002), 1019–1024.
146. Fronczeck, R., Overeem, S., Lee, S.Y.Y., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007), 1577–1585.
147. Tannickal, T.C., Lai, Y.Y., Siegel, J.M., Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007), 1586–1595.
148. Bauman, C., Ferini-Strambi, L., Waldvogel, D., et al. Parkinsonism with excessive daytime sleepiness: a narcolepsy-like disorder?. J Neurol 252 (2005), 139–145.
149. Drouot, X., Moutereau, S., Nguyen, J.P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61 (2003), 540–543.
150. Abbot, R.D., Ross, G.W., White, L.R., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65 (2005), 1442–1446.
151. Van Hilten, J.J., Hoogland, G., van der Velde, E.A., et al. Diurnal effects of motor activity and fatigue in Parkinson's disease. J Neurol Neurosurg Psychiatry 56 (1993), 874–877.
152. Friedman, J.H., Friedman, H., Fatigue in Parkinson's disease. Neurology 43 (1993), 2016–2018.
153. Karlsen, K., Larsen, J.P., Tandberg, E., Jorgensen, K., Fatigue in patients with Parkinson's disease. Mov Disord 14 (1999), 237–241.
154. Larsen, J.P., Karlsen, K., Tandberg, E., Clinical problems in nonfluctuating patients with Parkinson's disease: a community-based study. Mov Disord 15 (2000), 826–829.
155. Lou, J.S., Kearns, G., Oken, B., et al. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 16 (2001), 190–196.
156. Shulman, L.M., Taback, R., Rabinstein, A.A., Weiner, W.J., Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 8 (2002), 193–197.
157. Friedman, J.H., Brown, R.G., Comella, C., et al. Fatigue in Parkinson's disease: a review. Mov Disord 22 (2007), 297–308.
158. Shulman, L.M., Taback, R.L., Bean, J., Weiner, W.J., Comorbidity of the non-motor symptoms of Parkinson's disease. Mov Disord 16 (2001), 507–510.
159. Alves, G., Wentzel-Larsen, T., Larsen, J.P., Is fatigue an independent and persistent symptom in patients with Parkinson disease?. Neurology 63 (2004), 1908–1911.
160. Brown, R.G., Dittner, A., Findley, L., Wessely, S.C., The Parkinson fatigue scale. Parkinsonism Relat Disord 11 (2005), 49–55.
161. Andersen, J., Aabro, E., Gulmann, N., et al. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 62 (1980), 210–219.
162. Mendonça, D.A., Menezes, K., Jog, M.S., Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 22 (2007), 2070–2076.
163. Quinn, N.P., Koller, W.C., Lang, A.E., et al. Painful Parkinson's disease. Lancet 1 (1986), 1366–1369.
164. Quittenbaum, B.H., Grahn, B., Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord 10 (2004), 129–136.
165. Buzas, B., Max, M.B., Pain in Parkinson disease. Neurology 62 (2004), 2156–2157.
166. Ford, B., Pain in Parkinson's disease. Clin Neurosci 5 (1998), 63–72.
167. Tinazzi, M., Del Vesco, C., Fincati, E., et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006), 822–825.
168. Ford, B., Louise, P., Greene, P., et al. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 11 (1996), 421–426.
169. Djaldetti, R., Shifrin, A., Rogowski, Z., et al. Quantitative measurement of pain sensation in patients with Parkinson's disease. Neurology 62 (2004), 2171–2175.
170. O'Sullivan, S.S., Williams, D.R., Gallagher, D.A., et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 23 (2008), 101–106.
171. Hillen, M.E., Sage, J.I., Non-motor fluctuations in patients with Parkinson's disease. Neurology 47 (1996), 1180–1183.
172. Dhawan, V., Medcalf, P., Stegie, F., et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm 112 (2005), 661–668.
173. Etchepare, F., Rozenberg, S., Mirault, T., et al. Back problems in Parkinson's disease: an underestimated problem. Joint Bone Spine 73 (2006), 298–302.
174. Broetz, D., Eichner, M., Gasser, T., et al. Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord 22 (2007), 853–856.
175. Factor, S.A., Brown, D.L., Molho, E.S., Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 15 (2000), 167–169.
176. Panchetti, C., Albani, G., Martignoni, E., et al. “Off” painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10 (1995), 333–336.
177. Loher, T.J., Burgunder, J.M., Weber, S., et al. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 73 (2002), 395–399.
178. Witjas, T., Kaphan, E., Régis, J., et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 22 (2007), 1729–1734.
179. Djaldetti, R., Yust-Katz, S., Kolianov, V., et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 30 (2007), 201–205.
180. Lang, A.E., Johnson, K., Akathisia in idiopathic Parkinson's disease. Neurology 37 (1987), 477–481.
181. Comella, C.L., Goetz, C.G., Akathisia in Parkinson's disease. Mov Disord 9 (1994), 545–549.
182. Ondo, W.G., Vuong, K.D., Jankovic, J., Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59 (2002), 421–424.
183. Tan, E.K., Lum, S.Y., Wong, M.C., Restless legs syndrome in Parkinson's disease. J Neurol Sci 196 (2002), 33–36.
184. Iranzo, A., Comella, C.L., Santamaría, J., Oertel, W., Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord 22:Suppl 18 (2007), 424–430.
185. Nomura, T., Inoue, Y., Nakashima, K., Clinical characteristics of restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 250 (2006), 39–44.
186. Walters, A.S., LeBrocq, C., Passi, V., et al. A preliminary look at the percentage of patients with restless legs syndrome who also have Parkinson's disease, essential tremor or Tourette syndrome in a single practice. J Sleep Res 12 (2003), 343–345.
187. Kedia, S., Moro, E., Tagliati, M., et al. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 63 (2004), 2410–2412.
188. Driver-Dunckley, E., Evidente, V.G.H., Adler, C.H., et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 21 (2006), 1287–1289.
189. Gonera, E.G., Van't Hof, M., Berger, H.J.C., et al. Symptoms and duration of the premotor phase in Parkinson's disease. Mov Disord 12 (1997), 871–876.
190. Becker, G., Müller, A., Braune, S., et al. Early diagnosis of Parkinson's disease. J Neurol 249:Suppl 3 (2002), 40–48.
191. Awerbuch, G.I., Sandyk, R., Autonomic functions in the early stages of Parkinson's disease. Int J Neurosci 74 (1994), 9–16.
192. Abbott, R.D., Petrovitch, H., White, L.R., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 (2001), 456–462.
193. Ashraf, W., Pfeiffer, R.F., Park, F., et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 12 (1997), 946–951.
194. Camilleri, M., Bharucha, A.E., Gastrointestinal dysfunction in neurologic disease. Semin Neurol 16 (1996), 203–216.
195. Ueki, A., Otsuka, M., Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 251:Suppl 7 (2004), 18–23.
196. Gao, X., Chen, H., Schwarzschild, M., et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol 166 (2007), 1446–1450.
197. Minguez-Castellanos, A., Chamorro, C.E., Escamilla-Sevilla, F., et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 68 (2007), 2012–2018.
198. Doty, R.L., Deems, D.A., Stellar, S., Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38 (1988), 1237–1244.
199. Tissingh, G., Berendse, H.W., Bergmans, P., et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 16 (2001), 41–46.
200. Stern, M., Doty, R.L., Dotti, M., et al. Olfactory function in Parkinson's disease subtypes. Neurology 44 (1994), 266–268.
201. Ross, W., Petrovitch, H., Abbott, R.D., et al. Association of olfactory dysfunction with risk of future Parkinson's disease. Mov Disord 20:Suppl 10 (2005), 129–130.
202. Ross, G.W., Abbott, R.D., Petrovitch, H., et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21 (2006), 2062–2067.
203. Sommer, U., Hummel, T., Cormann, K., et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19 (2004), 1196–1202.
204. Markopoulou, K., Larsen, K.W., Wszolek, E.K., et al. Olfactory dysfunction in familial parkinsonism. Neurology 49 (1997), 1262–1267.
205. Montgomery, E.B., Baker, K.B., Lyons, K., Koller, W.C., Abnormal performance on the PD test battery by asymptomatic first degree relatives. Neurology 52 (1999), 757–762.
206. Berendse, H.W., Booij, J., Francot, G.M.J.E., et al. Subclinical dopaminergic dysfunction in symptomatic Parkinson's disease patients’ relatives with a decreased sense of smell. Ann Neurol 50 (2001), 34–41.
207. Boeve, B.F., Silber, M.H., Ferman, T.J., et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleopathy. Mov Disord 16 (2001), 622–630.
208. Postuma, R.B., Lang, A.E., Massicotte-Marquez, J., Montplaisir, J., Potential early markers of Parkinson's disease in idiopathic REM sleep behavior disorder. Neurology 66 (2006), 845–851.
209. Stiasny-Kolster, K., Doerr, Y., Möller, J.C., et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alfa-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 (2005), 126–137.